A phase III clinical trial demonstrated the advantage of denosumab over zoledronic acid (ZA) in delaying the first on-study and subsequent skeletal-related events (SREs) in patients with prostate cancer (PC). Recently, generic ZA became available. The purpose of this study was to examine the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC. Methods: An excel-based Markov model was constructed with 4-week model cycles to analyze the cost-effectiveness of the treatments from the perspective of Ministry of Health with a 10-year time horizon for PC cohort. Direct costs in 2014 tenge (tg) included costs of drug, adverse event and SRE (pathologic fracture, surgery to bone, radiation to bone, spinal cord compression) treatment. A discount rate of 3% per year was applied. Effectiveness was appraised based on the number of SREs. The health states were defined according to SRE occurrence, SRE history and death. The model assumed that a maximum of 1 SRE could occur in each cycle. Transition probabilities were derived from the relevant phase III trials. Results were present in the incremental total cost per SRE avoided. One-way sensitivity analyses were performed to examine the robustness of the model. Results: Over 10-year period, denosumab incurred 103091 tg higher costs than brand ZA, 677133 tg higher costs than generic ZA, 0.58 fewer SREs per PC patient; The estimated incremental total direct costs per SRE avoided with the use of denosumab were 177743 tg (instead of brand ZA) and 1167470 tg (instead of generic ZA). Results were robust to one-way sensitivity analyses. Conclusions: With assumption that brand and generic ZAs are equally effective, denosumab seems to be superior alternative for brand ZA (insignificant difference in costs), and costly alternative for generic ZA from a perspective of Ministry of Health of Republic of Kazakhstan.
Introduction
• Bone mass loss (BML) is one of the adverse effects of oncological chemotherapy, especially in cases of hormonal types of cancer, such as a prostate cancer (PC). [1] BML is strongly associated with skeletal-related events (SREs), [2] therefore decreases the quality of patient's life and increases the economic burden for healthcare expenditures. [3] • Denosumab is a fully human monoclonal antibody (IgG2) that specifically binds to human RANKL. Like osteoprotegerin, this prevents binding of RANKL to RANK on osteoclasts and inhibits the downstream signalling that induces osteoclast activation, leading to reduction of bone resorption and disruption of the vicious circle of bone metastases. It showed an advantage over zoledronic acid (ZA) in delaying the first-onstudy and subsequent SREs in adults with PC in several phase III clinical trials. [5] Since recently generic ZA became available, the purpose of present study was to access the cost-effectiveness of denosumab compared to brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC.
Methods
• A Markov model was constructed in the Excel with 4-week model cycles to analyse the cost-effectiveness of the treatments from the perspective of Ministry of Health (MoH) with a 10-year time horizon for PC cohort.
• Appearance of SREs was selected as the primary endpoint in majority of the phase III RCTs, therefore the total incremental cost per SRE avoided is used as a measure of outcomes in this study , which is consistent with metrics of cost-effectiveness in previously published economic analyzes of prevention of SREs in cancer patients.
• The model ( Figure 1 ) assumed that a maximum of 1 SRE could occur in each cycle. Health states were defined according to SRE occurrence, SRE history and death.
• Effectiveness was appraised based on the number of SREs. Transition probabilities were derived from the literature. [3, 4] • One-way sensitivity analyses were performed to examine the robustness of model.
Results
• The cumulative amount of SREs during the decade was 135.29 for the treatment of a hypothetical PC cohort in the ZA group and 91.14 in the group denosumab. It is noted that 80 out of 135 of SREs in the denosumab group occurred in the first six years, while at the same stage in the ZA group there were 119 SREs. The relative effectiveness of therapy denosumab for 10 years is -44.15 SREs, in other words denosumab therapy could prevent 44.15 SREs in 10 years if was chosen instead of ZA.
• Over 10-year period, denosumab incurred approximately 171 million tenge, brand ≈ ZA 163 million tenge and generic ZA ≈ 119 million tenge.
Conclusions
• The study is one of the first compared the cost-effectiveness of denosumab with the brand and/or generic versions of ZA in the prevention of SREs in patients with PC from the perspective of MoH of Kazakhstan.
• With assumption that brand and generic ZAs are equally effective in the prevention of SREs in PC patients, denosumab showed dominance in costeffectiveness over the brand ZA since it at the same input intensities (difference less than 4.5% per annum ) prevents 33% more SREs. Incremental total cost per SRE avoided for denosumab compared to generic ZA was about 1,16 million tenge..
• In other words, denosumab is more cost-effective as compared to the brand ZA, and is more effective and more costly (NB: with the cost-effectiveness threshold of WHO) in comparison with generic ZA from the perspective of MoH of Kazakhstan.
• These findings may better inform payers regarding formulary inclusion and reimbursement in the treatment of patients with PC and bone metastases. • Direct costs in 2014 tenge (1 USD = 184 tg) included costs of the drug (60 mg of denosumab twice a year, 4 mg/5ml of ZA once a year), management of SRE (such as pathologic fracture, surgery to bone, radiation to bone, spinal cord compression) and adverse events treatment. All costs were discounted for 3% per year. • Overall, over a 10-year period, denosumab incurred 103091 tenge higher costs than brand ZA, 677133 tenge higher costs than generic ZA, 0.58 fewer SREs per PC patient.
• The estimated incremental total direct costs per SRE avoided with the use of denosumab were 177743 tenge (instead of brand ZA) and 1167470 tenge (instead of generic ZA).
• Results were robust to oneway sensitivity analyses.
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